LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 761

Search options

  1. Book: Cancer stem cells: the promise and the potential

    Ajani, Jaffer A.

    (Seminars in oncology ; 42,2, Suppl. 1)

    2015  

    Author's details Jaffer A. Ajani ..., guest ed
    Series title Seminars in oncology ; 42,2, Suppl. 1
    Collection
    Language English
    Size S17 S. : Ill.
    Publisher Saunders
    Publishing place Philadelphia, Pa
    Publishing country United States
    Document type Book
    HBZ-ID HT018674786
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 1348 -42,Suppl.1- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.

    Rogers, Jane E / Ajani, Jaffer

    Current oncology (Toronto, Ont.)

    2024  Volume 31, Issue 2, Page(s) 769–777

    Abstract: Gastric adenocarcinoma (GAC) continues to be a prevalent worldwide malignancy and a leading cause of cancer death, and it is frequently cited as incurable. Targeted therapy in GAC has lagged behind other solid tumors. The human epidermal growth factor ... ...

    Abstract Gastric adenocarcinoma (GAC) continues to be a prevalent worldwide malignancy and a leading cause of cancer death, and it is frequently cited as incurable. Targeted therapy in GAC has lagged behind other solid tumors. The human epidermal growth factor receptor-2 (HER-2) represented the single target in GACs for many years, seen in approximately 20% of patients with advanced GAC. Recent advances in management now include the addition of immunotherapy checkpoint inhibition to select front-line advanced GACs. Unfortunately, outcomes remain poor for most patients. We anticipate finding a key to future discoveries in GACs in next-generation sequencing and more targeted approaches. Claudin 18.2 (CLDN18.2) has emerged as a therapeutic target in GACs. CLDN18.2 is reportedly expressed in 14-87% of GACs, and CLDN18.2 is available for monoclonal antibody (mAb) binding as it is expressed on the outer cell membrane. Here, we review the exploration of CLDN18.2 as a target in GACs via the use of zolbetuximab (IMAB362). Zolbetuximab is now under priority FDA review for GACs, and we eagerly await the review outcome.
    MeSH term(s) Humans ; Antibodies, Monoclonal/adverse effects ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/pathology ; Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Immunotherapy ; Claudins/therapeutic use
    Chemical Substances zolbetuximab (TF5MPQ8WGY) ; Antibodies, Monoclonal ; CLDN18 protein, human ; Claudins
    Language English
    Publishing date 2024-02-01
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 1236972-x
    ISSN 1718-7729 ; 1198-0052
    ISSN (online) 1718-7729
    ISSN 1198-0052
    DOI 10.3390/curroncol31020057
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4305: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Impediments to therapeutic advances for patients with gastroesophageal adenocarcinoma.

    Ajani, Jaffer A

    Translational gastroenterology and hepatology

    2021  Volume 6, Page(s) 49

    Language English
    Publishing date 2021-07-25
    Publishing country China
    Document type Editorial
    ISSN 2415-1289
    ISSN (online) 2415-1289
    DOI 10.21037/tgh.2020.03.07
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Recent advances in the management of gastric adenocarcinoma patients.

    Rogers, Jane E / Ajani, Jaffer A

    Faculty reviews

    2023  Volume 12, Page(s) 2

    Abstract: Gastric adenocarcinomas are a significant cause of cancer and cancer death, globally. The curative approach for those with diagnosed localized disease is with surgical resection and an adjunctive approach of perioperative chemotherapy, postoperative ... ...

    Abstract Gastric adenocarcinomas are a significant cause of cancer and cancer death, globally. The curative approach for those with diagnosed localized disease is with surgical resection and an adjunctive approach of perioperative chemotherapy, postoperative adjuvant therapy, or postoperative chemoradiation. Unfortunately, a universal standard approach is lacking for adjunctive therapy which in part has limited the progress achieved in this area. Metastatic disease is common in the Western world at diagnosis. Metastatic disease is treated palliatively with systemic therapy. Targeted therapy has stalled in approvals in gastric adenocarcinomas. Recently, we have seen the exploration of promising targets along with the addition of immune checkpoint inhibitors in select patients. Here, we review recent advances seen in gastric adenocarcinomas.
    Language English
    Publishing date 2023-02-21
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2732-432X
    ISSN (online) 2732-432X
    DOI 10.12703/r/12-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Book: Gastrointestinal cancer

    Ajani, Jaffer A.

    (M. D. Anderson Cancer Care Series)

    2005  

    Author's details Jaffer A. Ajani ... ed
    Series title M. D. Anderson Cancer Care Series
    Keywords Gastrointestinal Neoplasms / therapy ; Gastrointestinal Neoplasms / diagnosis
    Language English
    Size XV, 394 S. : Ill., graph. Darst., 61 schw.-w. Abb., 40 schw.-w. Fotos, 21 schw.-w. Zeichn.
    Publisher Springer
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT014226097
    ISBN 0-387-22090-9 ; 978-0-387-22090-1
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2005 A 362 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Defining the role of upfront immune checkpoint inhibition in advanced HER-2 negative gastric or gastroesophageal junction adenocarcinoma.

    Rogers, Jane E / Ajani, Jaffer A

    Annals of palliative medicine

    2022  Volume 11, Issue 6, Page(s) 2180–2183

    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Esophageal Neoplasms/drug therapy ; Esophageal Neoplasms/pathology ; Esophagogastric Junction/pathology ; Humans ; Immune Checkpoint Inhibitors ; Stomach Neoplasms/drug therapy
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2022-05-31
    Publishing country China
    Document type Editorial
    ZDB-ID 2828544-X
    ISSN 2224-5839 ; 2224-5839
    ISSN (online) 2224-5839
    ISSN 2224-5839
    DOI 10.21037/apm-22-581
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go?

    Rogers, Jane E / Ajani, Jaffer A

    Expert opinion on pharmacotherapy

    2022  Volume 23, Issue 17, Page(s) 1893–1902

    Abstract: Introduction: Esophageal cancer (EC) represents a complicated heterogenous group of malignancies. ECs are divided broadly into two types, histologically: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). Historically, EC ... ...

    Abstract Introduction: Esophageal cancer (EC) represents a complicated heterogenous group of malignancies. ECs are divided broadly into two types, histologically: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). Historically, EC study designs have used bucket type groupings (all subtypes and/or all gastroesophageal cancers) reducing contribution to developing precision oncology.
    Areas covered: Surgery remains the curative modality for resectable disease with reasonable patient physiology. Trimodality is recommended for localized ESCC. An exception is cervical EC. For EAC, preoperative chemoradiation or perioperative chemotherapy is utilized. For those who undergo trimodality, nivolumab is recommended as an adjuvant therapy for those with a non-pathological complete response (pCR). Additionally, immunotherapy and other targets have been added to advanced EC treatment.
    Expert opinion: Organ sparing approaches for localized tumors are starting to be investigated in many solid tumors and have been standard approaches for decades in certain tumors (i.e. certain head and neck tumors and anal SCCs). pCR differs between esophageal histologies with trimodality indicating potential of discriminating localized approaches. To determine if a watch and wait approach is feasible, prospectively correlating clinical complete response to pCR is needed, determining the best active surveillance strategy, and the best use of tools like liquid biopsies.
    MeSH term(s) Humans ; Adenocarcinoma/drug therapy ; Esophageal Neoplasms/drug therapy ; Esophageal Squamous Cell Carcinoma/drug therapy ; Precision Medicine ; Nivolumab/therapeutic use ; Combined Modality Therapy
    Chemical Substances Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2022-11-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2022.2140585
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Book: Irinotecan and other agents in lung cancer

    Ajani, Jaffer A.

    (Proceedings of The University of Texas M. D. Anderson Cancer Center Investigators' Workshop ; 2 ; Oncology ; 17,7, Suppl. 7)

    2003  

    Author's details guest ed. Jaffer A. Ajani
    Series title Proceedings of The University of Texas M. D. Anderson Cancer Center Investigators' Workshop ; 2
    Oncology ; 17,7, Suppl. 7
    Collection
    Language English
    Size 40 S. : graph. Darst.
    Publisher PRR
    Publishing place Melville, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT013819626
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 3168 -17,Suppl.7- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Book ; Conference proceedings: Irinotecan in the management of multiple tumor types

    Ajani, Jaffer A.

    highlights from the 6th University of Texas M. D. Anderson Cancer Center investigators' workshop [July 16 - 20, 2003, in Amelia Island, Florida]

    (Oncology ; 18,14, Suppl. 14)

    2004  

    Institution M. D. Anderson Cancer Center
    Author's details guest ed. Jaffer A. Ajani
    Series title Oncology ; 18,14, Suppl. 14
    Collection
    Language English
    Size 64 S. : graph. Darst.
    Publisher PRR
    Publishing place Melville, NY
    Publishing country United States
    Document type Book ; Conference proceedings
    HBZ-ID HT014299505
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 3168 -18,Suppl.14- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Book ; Conference proceedings: Research driven clinical approaches in gastrointestinal oncology

    Adam, René / Ajani, Jaffer A.

    [selected proceedings ... held in Paris, France on February 1 - 2, 2006]

    (Seminars in oncology ; 34,2, Suppl. 1)

    2007  

    Title variant Research-driven clinical approaches in gastrointestinal oncology
    Institution International Society of Gastrointestinal Oncology
    Event/congress European Gastrointestinal Conference (2006, Paris)
    Author's details ICACT ISGIO European Gastrointestinal Conference 2006. Jaffer A. Ajani, guest ed. Contributors René Adam
    Series title Seminars in oncology ; 34,2, Suppl. 1
    Collection
    Language English
    Size S42 S. : Ill., graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia, Pa
    Publishing country United States
    Document type Book ; Conference proceedings
    HBZ-ID HT015102204
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 1348 -34,2,Suppl.1- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top